Monday, December 18, 2017

Omalizumab (Xolair) linked to Cardiovascular Adverse Events

The popular asthma medication Xolair ,used in patients with moderate to severe asthma , was recently associated with adverse cardiovascular adverse events from the ongoing interim safety study entitled “Evaluating the Clinical Effectiveness and Long Term Safety in Patients with Moderate to Severe Asthma (EXCELS).”

Vitamin D Deficiency in Asthma

Asthma is a respiratory disease characterized by airway hyper-responsiveness and inflammation Asthma has many contributing factors including genetics, environment and food allergies, nutritional status and stress to name a few. Asthma prevalence continues to increase worldwide and industrialized nations furthest from the equator have the highest prevalence.

Asthma – Focusing on the Source

Asthma has become one of the most common chronic childhood illnesses with a significant impact on quality of life. What most parents don’t realize is that the majority of doctors only treat the symptoms – difficulty breathing, wheezing, etc – instead of the cause.